今年以来，在产业各方的协同努力下，我国生物制造技术快速突破并加快向各领域渗透，政策支持体系 日益完善，产业发展前景更加广阔，展现出生物制造作为未来产业的巨大潜力和强劲动力。 华东理工大学生物反应器工程全国重点实验室叶邦策团队构建基于肿瘤微环境响应的自调控智能工程菌 系统，实现了对肿瘤组织的精准靶向定植；全国首个正式投产的天然产物生物制造示范线在上海化学工 业区启动；吉林化纤（000420）年产3.5万吨生物质人造丝项目一期2万吨生产线全面达产…… 生物制造加速向各领域渗透 今年上半年，伴随基因工程、合成生物学等核心技术的快速进步，生物制造越来越广泛地应用到医药、 材料、农业等多个领域，带动传统生产方式的变革与发展。 在生物医药领域，中国科学院刘陈立团队以沙门氏菌为底盘细胞，利用实体肿瘤细胞相对正常细胞的缺 氧环境，开发了新型的抗肿瘤菌株DB1，能精准识别肿瘤并激活免疫系统；中国科学院刘光慧团队用合 成生物学手段对干细胞的长寿基因通路进行重编程，提高了抗氧化和祖细胞抗衰老等能力…… 在生物基材料领域，上海蓝晶微生物科技有限公司创始人张浩千团队自主研发的生物混动技术体系，使 聚羟基脂肪酸酯（PHA）单位产量与碳源 ...

Core Viewpoint - The article discusses the advancements in synthetic biology and the key technologies selected by Anhui Province for the 2025 manufacturing "recruitment and innovation" initiative, highlighting the focus on bio-manufacturing and its applications in various industries [2][3]. Summary by Sections Global Policy Progress - Anhui Province's Industrial and Information Technology Department announced a public list of 325 key technology tasks and 3 innovation tasks for small, medium, and large enterprises as part of the 2025 manufacturing initiative [2]. Key Technologies Involved - The selected tasks include several related to synthetic biology, such as: - New anaerobic fermentation processes for mixed raw materials with a biogas yield of over 1.1 m³/m³·d and methane concentration above 65% [4]. - Biogas purification technology with a recovery rate of ≥99% [4]. - Development of biogas liquefaction equipment meeting national quality standards [4]. - High-value conversion of agricultural waste into biogas with specific quality parameters [4]. - Research on antibody molecules with specific antigen binding capabilities [4]. - AI-assisted enzyme directed evolution for the synthesis of specific compounds [4]. Industrial Applications - The article outlines various applications of synthetic biology technologies, including: - Production of amino acids with specific fermentation yields and glucose conversion rates [5]. - Development of microbial agents with high fermentation efficiency and specific bacterial counts [5]. - Establishment of standards and patents for new biomanufacturing processes [5]. Conclusion - The focus on synthetic biology in Anhui's manufacturing strategy indicates a significant push towards innovation in bio-manufacturing, aiming to enhance productivity and sustainability across multiple sectors [2][3].

Core Insights - The article highlights the rapid development of the life and health industry in Wuhan's "Optics Valley," positioning it as a new global hub for the sector [1][9] - The 17th China Biotech Industry Conference showcased nearly a thousand cutting-edge technologies and innovations, emphasizing the region's strong competitive edge in the industry [1][2] Group 1: Industry Development - The conference theme was "Biotechnology Empowering the Future, Biomanufacturing Reshaping the World," featuring five main sections including policy interpretation and international cooperation [2] - The event facilitated deeper international and domestic collaborations, with representatives from 23 countries engaging in discussions to build cross-regional cooperation networks [3] Group 2: Innovations and Achievements - Significant innovations were presented, including the world's first "rice-derived" recombinant human albumin injection and a non-invasive brain-machine interface device [6][8] - The region has over 400 new drugs in clinical trials and more than 1,800 medical devices approved for market, showcasing its robust innovation capabilities [8] Group 3: Economic Impact - The life and health industry in Wuhan is projected to exceed 554.6 billion yuan, making it the largest in Central China, while the overall health industry in Hubei province is expected to surpass 1 trillion yuan [9] - The Optics Valley has established itself as a leading area for biopharmaceuticals, medical devices, and agricultural biotechnology, housing over 4,200 related enterprises [8][9]

Core Insights - The article highlights the unique path taken by Yikole Biotechnology in the biomanufacturing sector, emphasizing its successful transition from research to large-scale production, which is critical for survival in the industry [1][2]. Group 1: Company Overview - Yikole has launched nearly 20 products in its ten years of operation, achieving significant market share in several of them [1]. - The company recently completed a strategic investment of 450 million yuan from Guotou Juli [1]. Group 2: Technological Innovation - Yikole has developed a platform-based technology system that integrates design, modification, and application, breaking the "R&D to mass production" bottleneck [2]. - The company has built a library of over 60,000 enzyme entities covering 20 types of industrial reactions, enabling rapid adaptation to different product development needs [2]. Group 3: Product Development - Yikole is the only company approved by the National Health Commission to produce high-end sweetener Steviol Glycoside M using enzyme conversion methods, with new sugar-reduced beverages already launched [3]. - The company has also become one of the first licensed producers of human milk oligosaccharides in China, with its 2'-fucosyllactose receiving approval in October 2023 [3]. Group 4: Market Strategy - Yikole's management team consists of experienced professionals from the biomanufacturing sector, ensuring a unified vision for addressing industry pain points and creating marketable products [4]. - The company is focusing on upstream raw materials like methanol and carbon dioxide, which are not constrained by arable land or food supply, aiming to reduce production costs and promote a green transition [5]. - Yikole is forming joint ventures with leading companies in specific fields to leverage their market resources and facilitate product commercialization [5].

7月美妆行业融资市场一度遇冷，这一低迷态势在8月迎来显著扭转，赛道整体焕发生机，回暖行情清晰显现。 从美妆头条的不完全统计数据来看，8月美妆领域共落地10起企业投融资案例，涉及资金总额约6亿元，为行业注入一剂强心针。 01 10起融资落地 8月美妆行业"破冰回暖" 进入8月份以来，美妆行业明显开始回暖，从投融资案例就能窥见一二。 据美妆头条不完全统计，8月份美妆行业共发生10起相关企业投融资案例，资金总额6亿左右。 整体来看，10起美妆行业的投融资呈现出多元化趋势，主要集中在品牌、合成生物、医美等领域。 从融资金额来看，除了1起融资事件未披露金额，1000万以上的项目数量占比最高，亿元项目高达3起，医美赛道拿下最大一笔，金额高达数亿元，成为资 金聚焦的核心板块。 从融资规模来看，相较于7月，8月份融资事件和融资金额都大幅度上涨，融资事件数量增加6起。 02 合成生物成为"宠儿" 3家企业获资本加持 自"新质生产力"被提出后，合成生物学的热度就一直没下来过，不仅成为化妆品产业的热点话题，更成为融资的"关键词"。 8月份，就有3家合成生物企业获得融资，赛道热度可见一斑。 据外媒报道，8月，生物科技美容领军者Deb ...

Group 1 - The core viewpoint of the article highlights the establishment of a joint venture between Yihai Kerry (Golden Dragon Fish) and Xinhua Yang to enter the synthetic biology industry, focusing on the production of various enzymes and bio-based materials [2][4]. - Yihai Kerry is a significant player in the agricultural and food processing sector in China, involved in multiple industries including edible oil refining, food ingredients, and deep processing of grains [2][4]. - Xinhua Yang is recognized as one of the top ten enzyme preparation manufacturers in China, specializing in microbial ecological preparations [3]. Group 2 - The joint venture, named Xinhua Yang Yihai Kerry, aims to utilize synthetic biology technology to produce food-grade enzymes, feed enzymes, and other industrial enzymes, targeting global markets [4]. - By December 2024, Yihai Kerry plans to establish two companies with Fuxiang Pharmaceutical, focusing on the manufacturing and sales of food ingredients and pharmaceutical intermediates, with an expected annual production capacity of 200,000 tons [6]. - Fuxiang Pharmaceutical is noted for being the first company in China to achieve industrialization of filamentous fungal protein at a scale of over 1,000 tons, and is accelerating the construction of a project with an annual capacity of 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer [7].

Core Viewpoint - The article emphasizes the importance of talent acquisition in the field of synthetic biology and protein engineering, highlighting the need for skilled professionals to drive innovation and application in the industrial biotechnology sector [4][5]. Talent Demand - The Tianjin Institute of Industrial Biotechnology is inviting talented individuals from both domestic and international backgrounds to join its efforts in advancing the industrial biotechnology industry [4]. - The Multi-Peptide and Protein Engineering Research Center focuses on synthetic biology innovations, aiming to address challenges in resources, environment, health, and bio-manufacturing [4]. Research Center Overview - The center integrates various disciplines such as microbiology, molecular biology, biochemistry, structural biology, protein engineering, bioinformatics, and computational biology to enhance synthetic biology strategies [4]. Researcher Profile - Zhang Yanfei, a researcher and doctoral supervisor, leads the Multi-Peptide and Protein Engineering Research Center, with a strong academic background and extensive research experience in synthetic biology and metabolic engineering [5]. Job Opportunities - Positions available include Assistant Researcher and Special Research Assistant (Postdoctoral), with competitive salaries and additional funding opportunities from local government initiatives [8][10]. - The Tianjin Port Free Trade Zone offers a funding support of 300,000 yuan for outstanding postdoctoral researchers, which can be combined with the institute's salary [8]. Additional Benefits - Postdoctoral researchers who achieve significant results can apply for higher-level positions within the institute and receive competitive compensation and development opportunities [10][15]. - The institute provides various benefits, including social insurance, housing fund contributions, health check-ups, and paid annual leave [13][14]. Application Process - Applicants are required to submit their resumes and complete the application form, with a long-term open application period [12][18].

从产业生态搭建来看，中心已形成"龙头引领、梯队培育"的良好态势，引入了微康益生菌这一行业"隐 形冠军"——其拥有亚洲最大的益生菌菌种研发智能制造基地，产品获评拜耳制药全球最佳供应商。中 心还成功孵化益一科技、康科生物、修喵修勾科技、玖明医疗等企业，覆盖医疗健康、膳食营养、宠物 健康等细分领域，有效补全鼓楼合成生物产业链条。 活动现场签约的海尔生物、德悦普惠医疗、量准科技等项目，进一步覆盖细胞库建设、创新药筛选、生 物芯片研发等关键环节，多项目协同发力，将推动产业链从"单点突破"迈向"全链协同"。 本报讯(董翔鼓轩)近日，南京市鼓楼区与南京师范大学启动共建智能生物制造创新中心。据了解，该中 心将以合成生物学底层技术为核心，打造"1+1+N"创新模式，既依托南师大科研平台攻克核心技术，又 联动企业推动成果落地，真正破解"实验室突破难转化为产业产品"的痛点。 该中心管委会主任将由中国工程院院士、南京师范大学副校长黄和亲自担任。现场，黄和院士为微康益 生菌、纽邦生物、迪必尔生物工程、北极光等企业负责人颁发智能生物制造创新中心产业顾问聘书，邀 请行业力量共促产业发展。 ...

Core Viewpoint - China's biomanufacturing and biotechnology sectors are experiencing significant growth, with advancements in CAR-T cell therapy, biopharmaceuticals, and digital pathology, positioning the country as a global leader in these fields [3][5][10]. Group 1: Biopharmaceuticals - China ranks second globally in the number of CAR-T clinical research centers, with 388 centers as of 2024, reflecting a 60% increase from 2020 [7]. - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with the number of new drug approvals reaching a five-year high of 93 in 2024 [6][7]. - China is now the second-largest biopharmaceutical market globally, with a significant number of drugs in development, narrowing the gap with the United States [7]. Group 2: Biotechnology and Innovation - The report highlights that China leads globally in biotechnology patent applications and research personnel, with over 30% of new innovative drugs and research pipelines originating from the country [5][11]. - The establishment of 23 biomanufacturing bases across the country indicates a robust infrastructure supporting the growth of the biomanufacturing sector [5]. - The "National Innovative Drug Insight System" was launched to enhance the efficiency of drug development and address challenges in identifying quality projects and matching strategic resources [9]. Group 3: Digital Pathology and Medical Devices - The Hubei Pathology Big Data Database has become the second-largest globally, with 170,000 high-precision digital slices, expected to exceed 500,000 by the end of 2025 [8]. - China leads the world in medical device patent applications, accounting for nearly 70% of the global total, showcasing its strong research output in this field [8]. Group 4: Agricultural Biotechnology - The agricultural biotechnology market in China accounts for 23% of the global market, with significant advancements in genetically modified crops [12]. - The application of synthetic biology and gene editing is driving growth in biomanufacturing, with a focus on biopharmaceuticals, biomaterials, and bioenergy [12]. Group 5: Future Outlook - The global biomanufacturing market is projected to grow significantly, with estimates suggesting a rise from $4-5 trillion to $30 trillion by 2050, indicating a compound annual growth rate of 8.6% [11]. - The integration of artificial intelligence in life sciences is expected to enhance drug development efficiency and expand applications across various sectors, including healthcare and agriculture [12].

Core Viewpoint - Meihua Biological has successfully completed its share repurchase plan, signaling strong financial health and stability in its operations, while also focusing on expanding its global presence in the amino acid industry [1][4]. Group 1: Share Repurchase and Financial Performance - The company repurchased 48.5471 million shares, accounting for 1.70% of its total share capital, at a price range of 9.10 to 10.97 yuan per share, totaling 492 million yuan [2][3]. - The repurchased shares will be canceled, reducing the total share capital from 2.853 billion shares to 2.804 billion shares, and increasing the shareholding ratio of major shareholders from 33.34% to 33.92% [2][3]. - In the first half of 2025, the company reported a net profit of 1.768 billion yuan, a year-on-year increase of 19.96%, despite a slight decline in revenue [6]. Group 2: Business Strategy and Market Position - Meihua Biological has focused on its core business of amino acids, enhancing its competitive edge through international expansion and refined operations [1][5]. - The company has maintained a stable profit distribution policy, with cumulative cash dividends exceeding 12 billion yuan since its restructuring in 2010, and a record dividend payout of 1.699 billion yuan for 2024 [3][4]. - The company has a diversified product matrix, leading in the production of lysine and threonine globally, and ranking second in MSG production [5]. Group 3: Research and Development - Meihua Biological has increased its R&D investment, with total R&D expenses reaching 897 million yuan over two and a half years, reflecting a commitment to maintaining its technological leadership in the industry [7]. - The company has accelerated its international strategy, completing a cross-border acquisition that enhances its product offerings and strengthens its global supply chain position [7].